Genexine, a Korean biotech firm, said it would deliver a corporate presentation at the upcoming H.C. Wainwright Global Investment Conference in the U.S.

H.C. Wainwright, a U.S. investment bank, invites promising companies and holds a conference for investors twice a year.

The investment conference will be held both in-person and virtual from May 23-26. In addition, Genexine CEO Neil Warma’s presentation will be available on the conference website for 90 days.

Warma will introduce the company, pipeline development status, and business operation performance to global investors at the conference, Genexine said.

More specifically, the presentation will include the promotion of key pipelines, including GX-I7, investigational immunotherapy to treat triple-negative breast cancer (TNBC) and glioblastoma (GBM), and GX188E, a DNA vaccine candidate to treat cervical and head and neck cancer.

The presentation will be available on the online link at https://journey.ct.events/view/5e0fd34d-ea24-4a62-9922-cb8b47d40977.